When manufacturing pharmaceuticals, the risk of contaminants impacting pharmaceutical safety, efficacy and purity is real.
Contamination control is increasingly becoming a focus for regulatory bodies (although it has always been important), with the expectation to now have a documented Contamination Control Strategy (CCS) for pharmaceutical manufacturers.
"Contamination of a starting material or of a product by another material or product should be prevented…contamination of all products poses risk to patient safety dependent on the nature and extent of contamination"
PIC/S Guide to Good Manufacturing Practice for Medicinal Products PE-009-16 Part I Clause 5.18 (part)
CCS is a critical strategic document/plan that describes the contamination risk management strategy and associated governance to decide the continuous improvements and investment plans to prevent contamination. Therefore, developing such a document requires a cross-functional team of experts with good production, QRM, and regulatory knowledge.
So, what can you do to ensure your CCS complies with regulatory expectations?
Consider the following.
There is a multitude of potential sources of contamination; some are listed below:
Contamination Control is a set of systems and techniques that ensure the minimisation or reduction of contamination.
"A Quality Risk Management process…should be used to assess and control cross-contamination risks presented by the products manufactured"
PIC/S Guide to Good Manufacturing Practice for Medicinal Products PE-009-16 Part I, clause 5.20 (part)
"The outcome of the Quality Risk Management process should be the basis for determining the extent of technical and organisational measures required to control risks of cross-contamination."
PIC/S Guide to Good Manufacturing Practice for Medicinal Products PE-009-16 Part I, clause 5.21 (part)
Examples of technical measures:
Examples of organisational measures:
To start, the product quality needs to be defined, along with determining the contaminants of concern (the types). Then, determine the source of the contaminants and the routes of transmission. Following this, establish strategies to prevent contamination and implement monitoring and testing programs to detect contamination.
"Measures to prevent cross-contamination and their effectiveness should be reviewed periodically according to set procedures"
PIC/S Guide to Good Manufacturing Practice for Medicinal Products PE-009-16 Part I, clause 5.22
An initial risk assessment should be a critical step in implementing the CCS…but don’t ‘set and forget! The CCS should be considered a living document and can continually be strengthened. Ongoing risk assessment should be applied whereby the initial risk assessment for the area/facility/process should be periodically reviewed and updated as necessary.
In short, failure to maintain a CCS can lead to detrimental effects on the quality and safety of products. Your CCS must be robust!
For further information, SeerPharma offers courses SP6537: Contamination Control and SP6530: Changes to Annex 1 – Manufacture of Sterile Medicinal Products